Aminoglycoside-induced hearing deficits – a review of cochlear ototoxicity

Petersen, Lucretia; Rogers, Christine

doi:10.1080/20786190.2014.1002220

Cited by 51 publications

(50 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The damage starts at high-frequency coding cochlear base and progresses towards the apex. 19,20 In our study all children received treatment as per MCP841 protocol which include 12 doses of vincristine at a dose of 1.4 mg/m 2 between baseline and follow up evaluation and cranial irradiation of 1800cGy in those aged above 3 years. Antibiotics were selected at recommended doses depending on the clinical demands.…”

Section: Resultsmentioning

confidence: 99%

Does Vincristine affect Cochlear function in children with acute lymphoblastic leukaemia?

Rao

Kumar²,

Bhat

et al. 2016

Bangla J Med

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Does Vincristine affect Cochlear function in children with acute lymphoblastic leukaemia?

Rao

Kumar²,

Bhat

et al. 2016

Bangla J Med

View full text Add to dashboard Cite

show abstract

“…Developing countries, such as South Africa, utilize kanamycin because it is an easily accessible and inexpensive multidrugresistant tuberculosis treatment (Harris et al, 2012;Peterson & Rogers, 2015). Kanamycin is commonly used alongside other aminoglycosides, such as capreomycin and amikacin, to treat multidrug-resistant tuberculosis, Mycobacterium avium complex, as well as other non-tuberculous mycobacteria and pyelonephritis (Peloquin et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

D-methionine (D-met) significantly reduces kanamycin-induced ototoxicity in pigmented guinea pigs

Campbell

Martin

Meech

et al. 2016

International Journal of Audiology

View full text Add to dashboard Cite

Objective: Test D-methionine (D-met) as an otoprotectant from kanamycin-induced ototoxicity and determine the lowest maximally protective D-met dose. Design: Auditory brainstem responses (ABR) were measured at 4, 8, 14, and 20 kHz at baseline and two, four, and six weeks after kanamycin and D-met administration initiation. ABR threshold shifts assessed auditory function. Following six-week ABR testing, animals were decapitated and cochleae collected for outer hair cell (OHC) quantification. Study sample: Eight groups of 10 male pigmented guinea pigs were administered a subcutaneous kanamycin (250 mg/kg/dose) injection once per day and an intraperitoneal D-met injection (0 (saline), 120, 180, 240, 300, 360, 420, or 480 mg/kg/day) twice per day for 23 days. Results: Significant ABR threshold shift reductions and increased OHC counts (p 0.01) were measured at multiple D-met-dosed groups starting at two-week ABR assessments. A 300 mg/kg/day optimal otoprotective D-met dose provided 34-41 dB ABR threshold shift reductions and OHC protection. Lesser, but significant, D-met otoprotection was measured at lower and higher D-met doses. Conclusions: D-met significantly reduced ABR threshold shifts and increased OHC percentages compared to kanamycin-treated controls. Results may be clinically significant particularly for multidrug-resistant tuberculosis patients who frequently suffer from kanamycin-induced hearing loss in developing countries.

show abstract

“…Nephrotoxicity is reversible and clinically managed with hydration therapy, however ototoxicity is permanent and profoundly hinder the patient quality of life. [1][2][3] Aminoglycoside induced ototoxicity can be due to damage of vestibular system or auditory system or both. Amikacin, kanamycin and neomycin, are mainly cochleotoxic.…”

Section: Introductionmentioning

confidence: 99%

“…The incidence of amikacin induced vestibular ototoxicity vary from 7-28.5%. [1][2][3][4][5] Reporting here is an interesting case of amikacin induced vestibular ototoxicity.…”

Section: Introductionmentioning

confidence: 99%